New! Sign up for our free email newsletter.
Science News
from research organizations

Drug Combination Boosts Survival Rate In Head And Neck Cancers

Date:
May 15, 2005
Source:
Dana-Farber Cancer Institute
Summary:
Adding a third drug to a standard chemotherapy combination can dramatically improve the survival of patients with advanced head and neck cancer, according to a study led by researchers at Dana-Farber. Combination chemotherapy of cisplatin and 5-fu yields a 25 to 50 percent rate of complete pathological responses (the tumor disappeared). The new study found that adding docetaxel (Taxotere) to the cisplatin and 5-fu regimen increased the complete pathological response rate to 89 percent.
Share:
FULL STORY

ORLANDO, Fla.--Adding a third drug to a standard chemotherapy combination can dramatically improve the survival of patients with advanced head and neck cancer, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. The findings will be presented at the American Society of Clinical Oncology's annual meeting.

Previous studies have shown that using combination chemotherapy of cisplatin and 5-fu yields a 25 to 50 percent rate of complete pathological responses (the tumor disappeared). Robert Haddad, MD, and his colleagues found that adding the drug docetaxel (Taxotere) to the cisplatin and 5-fu regimen significantly increased the complete pathological response rate to 89 percent. The data (Abstract 5511) will be presented as a poster discussion session on Saturday, May 14, at 1 p.m., Level 4, 414.

Using data obtained from treating 72 patients with locally advanced squamous cell carcinoma of the head and neck, the researchers project that the three-drug combination would result in a 95 percent two-year survival rate and a 90 percent five-year survival rate. The majority of these patients have stage IV disease.

"These results are very encouraging and in all likelihood will translate into a significantly more effective treatment for patients with advanced head and neck cancer," says Haddad. "This patient population historically has had a poor prognosis, but, given these findings, the outlook is more hopeful."

The drug combination is given for three cycles as an initial treatment, known as induction chemotherapy, to shrink tumors prior to several weeks of intense treatment with additional chemotherapy given along with radiation. This "sequential therapy" has brought about the most successful results in patients with these stubborn cancers. Cancers of the head and neck are diagnosed in more than 40,000 people in the United States each year, with about 7,200 deaths.

Based on recent results of Phase III trials of the therapy and on the new data, Haddad, who is also an assistant professor at Harvard Medical School, and his colleagues propose that the three-drug combination be used as the new platform when using induction chemotherapy.

###

In addition to Haddad, the study's other authors are Lori Wirth, MD, Charles Norris, Jr., MD, Marshall Posner, MD, Yi Li, PhD, and Lindsey O'Donnell, Dana-Farber; Roy Tishler, MD, Brigham and Women's Hospital; Laura Goguen, MD, Joint Center for Otolaryngology; and Christopher Sullivan, MD, formerly of Dana-Farber and now at Wake Forest University Baptist Medical Center.

Dana-Farber Cancer Institute (www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.


Story Source:

Materials provided by Dana-Farber Cancer Institute. Note: Content may be edited for style and length.


Cite This Page:

Dana-Farber Cancer Institute. "Drug Combination Boosts Survival Rate In Head And Neck Cancers." ScienceDaily. ScienceDaily, 15 May 2005. <www.sciencedaily.com/releases/2005/05/050514205815.htm>.
Dana-Farber Cancer Institute. (2005, May 15). Drug Combination Boosts Survival Rate In Head And Neck Cancers. ScienceDaily. Retrieved June 18, 2024 from www.sciencedaily.com/releases/2005/05/050514205815.htm
Dana-Farber Cancer Institute. "Drug Combination Boosts Survival Rate In Head And Neck Cancers." ScienceDaily. www.sciencedaily.com/releases/2005/05/050514205815.htm (accessed June 18, 2024).

Explore More

from ScienceDaily

RELATED STORIES